Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal FluidBleich S. · Otto M. · Zerr I. · Kropp S. · Kretzschmar H.A. · Wiltfang J.
aDepartment of Psychiatry and Psychotherapy, Friedrich-Alexander-University, Erlangen-Nuremberg, bDepartment of Neurology, Georg-August-University Göttingen, cDepartment of Psychiatry and Psychotherapy, Medical School University, Hannover, and dInstitute of Neuropathology, Ludwig-Maximilians-University, Munich, Germany
Background: There is evidence that homocysteine contributes to various neurodegenerative disorders. Objective: To assess the values of homocysteine in patients with Creutzfeldt-Jakob disease (CJD) in both cerebrospinal fluid (CSF) and plasma. Methods: Study design: Case control study. Total homocysteine was quantified in CSF and plasma samples of CJD patients (n = 13) and healthy controls (n = 13). Results: Mean values in healthy controls: 0.15 µmol/l ± 0.07 (CSF) and 9.10 µmol/l ± 2.99 (plasma); mean values in CJD patients: 0.13 µmol/l ± 0.03 (CSF) and 9.22 µmol/l ± 1.81 (plasma). No significant differences between CJD patients and controls were observed (Mann-Whitney U, p > 0.05). Conclusions: The results indicate that the CSF and plasma of CJD patients showed no higher endogenous levels of homocysteine as compared to normal healthy controls. These findings provide no evidence for an additional role of homocysteine in the pathogenetic mechanisms underlying CJD neurodegeneration.
|Direct payment||This item at the regular price: USD 33.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00